Literature DB >> 27918224

Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) - Report 1: Epidemiology and Classification.

Elizabeth J Chen1, Muhammad Amir Bin Ismail2, Helen Mi2, Su Ling Ho2, Wee Kiak Lim2,3, Stephen C Teoh2,3, Rupesh Agrawal1,2.   

Abstract

PURPOSE: To report the epidemiology and classification of ocular inflammation at a tertiary eye care center in Singapore.
METHODS: Retrospective cohort study of the clinical records of consecutive new cases from the Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) database from 2004-2015.
RESULTS: A total of 2200 patients were studied from the OASIS database. The most common anatomic diagnosis was anterior uveitis (55.9%), posterior uveitis (17.5%), panuveitis (9.6%), and intermediate uveitis (4.7%). In addition, scleritis (6.1%), keratouveitis (2.8%), retinal vasculitis (2.2%), and episcleritis (1.2%) were observed. Etiology was established in 65.1%, with 35.2% of patients associated with non-infectious etiologies. The most common etiologies found were presumed tuberculosis (7.2%), followed by cytomegalovirus infection (6.9%), herpetic infection (6.3%), HLA-B27-associated anterior uveitis (4.2%), and ankylosing spondylitis (3.8%).
CONCLUSIONS: The pattern of ocular inflammation in Singapore has similarities with both Western and Asian populations. Anterior uveitis was the most common, with non-infectious etiologies being slightly more common than infectious etiologies.

Entities:  

Keywords:  Classification; OASIS; epidemiology; ocular inflammation; uveitis

Mesh:

Year:  2016        PMID: 27918224     DOI: 10.1080/09273948.2016.1249376

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  1 in total

1.  Concurrent presence of retinal hemorrhages in the setting of acute Vogt-Koyanagi-Harada syndrome - an unusual presentation.

Authors:  Sowkath Ali; Hnin Hnin Oo; Rupesh Agarwal; Peh Khaik Khee
Journal:  J Ophthalmic Inflamm Infect       Date:  2020-04-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.